We have improved the enzyme-linked immunosorbent assay for IgA-class antibodies to gliadin in serum by evaluating earlier publications. We also assess the value of measuring these antibodies when screening for adult celiac disease and monitoring dietary compliance. The test should be highly sensitive so that patients with a treatable condition are not misdiagnosed and, to avoid unnecessary investigation of normal subjects, the test should also be highly specific. A high predictive value of a negative test result is essential so that patients can be reassured that further investigation is unnecessary.
The test should be highly sensitive so that patients with a treatable condition are not misdiagnosed and, to avoid unnecessary investigation of normal subjects, the test should also be highly specific. A high predictive value of a negative test result is essential so that patients can be reassured that further investigation is unnecessary. Most patients with CD do not have obvious manifestations of the disorder but present with, e.g., mild ill health, anemia, or short stature (1) . The challenge is to find a screening test that can identifr such individuals.
The search for a screening test for CD has centered in recent years on measuring anti-gliadin antibodies in serum, a test that may be applied to many possible patients. The goals of the present study were to improve the technique for the measurement of IgA-type antibodies (AGA) by a critical appraisal of earlier publications and to evaluate the use of AGA both to detect CD and to monitor patient compliance with a gluten-free diet (GFD) .
MaterIals and Methods

Patients
Subjects without celiac disease. were reanalyzed after appropriate initial dilution of the sample in bovine serum so that the protein concentration of all samples was similar. dietary antigens, including bovine albumin, in CD (14, 
15).
To derive a reference range, we used two groups of subjects: a group with a normal small intestinal mucosa by biopsy (Group 1) and a larger group from the gastroenterology clinic, who had neither Crohn's disease nor ulcerative colitis and in whom there was no suspicion of CD (Group 3). Because the distribution of antibody concentrations did not differ significantly between the two groups, these were considered as a single control group for defining the reference range. None of the results for the 35 normal subjects (Group 2) exceeded the 95th percentile of the combined Groups 1 and 3, although the difference between them did not achieve statistical significance.
We believe that our combined Groups 1 and 3, although not entirely normal, form an appropriate control population because it is from other hospital patients that those with CD are being selected by the screening test. The variation in specificity in the studies reviewed (Table 4 ) results in part from differences in the selection of the control populations.
As have other researchers, we encountered some false positives among patients with ulcerative colitis and Crohn's disease. Of the 32 patients (Table 2) Of the 61 patients with untreated CD, all but five (Table 3) patients had not developed abnormal IgA antibody concentrations-which is difficult to explain, because all had small intestinal biopsies characteristic of CD. Two had dermatitis herpetiformis and at the time of biopsy had bowel symptoms consistent with celiac disease; both patients responded clinically to GFD. One was rebiopsied and showed improvement in the small bowel mucosa. Patient 14 presented with a severe anemia; small intestinal biopsy revealed a flat mucosa, typical of CD. A barium enema showed a carcinoma in the ascending colon, which was successfully resected. A repeat biopsy, four months after starting GFD, showed improvement of the mucosa with the return of villi. Patient 15 had CD diagnosed in childhood but at age 13 years returned to a normal diet. Although without symptoms, she requested a consultation to see if CD was still present. A small intestinal biopsy at age 20 years was flat, but she declined to follow a GFD. Paerregaard et al. (16) described three asymptomatic patients with flat small bowel biopsies, no evidence of malabsorption, and normal concentrations of anti-gliadin antibodies, which they suggested might be due to a less-widespread mucosal lesion. In support of this view, three of our four patients with normal anti-gliadin antibody concentrations had only slightly increased cellobiose/mannitol ratios. With a prevalence of CD of 5% among a gastroenterology clinic population suspected of having the disorder (17) and from the sensitivity (0.93) and specificity (0.95) data described here, we calculate the predictive value of a positive result as 50% and of a negative result, 99.7%.
After two years on a strict GFD, subjects with CD had normal AGA concentrations (Figure 1) . The test thus provides the clinician with useful, objective evidence of dietary compliance, which has become increasingly important in view of recent data showing that adherence to a strict GFD protects the patient from malignant complications (18) . Results of the test may also motivate patients to observe the diet more carefully.
In conclusion, we found that, in a large group of untreated celiac patients, >90% have high AGA concentrations and that the number of false positives from patients attending a gastroenterology clinic is low (5%). Because the predictive value of a positive test result is 50% in this population, the test can help the clinician decide which patients should have a small bowel biopsy; however, if suspicion is strong and there are other indications of CD, a biopsy should always be done, even if the antibody test result is negative. The test also provides objective evidence of compliance with GFD.
Why a very small number of untreated patients should have normal AGA concentrations is unclear and warrants further study.
